🟢 Milestone Pharmaceuticals is trading 6.61% up in pre-market after China’s NMPA approval of etripamil

Milestone Pharmaceuticals is trading at $1.29 (+6.61%) in pre-market after announcing China’s NMPA approval of etripamil nasal spray for adult PSVT on September 3.

• The approval marks etripamil’s first approval outside the United States.
• It triggers a $2 million milestone payment and could support additional commercial milestones and royalties through its China partnership.
• The company-specific regulatory catalyst is the clearest explanation for the pre-market gain.